Fact Sheet

Gene Therapies Could Reduce Hemophilia A Costs by about 63%–90%

Gene therapies could reduce Hemophilia A costs by about 63%–90% per patient over five years resulting in up to $1.8 million in potential savings. Gene therapies meet a previous unmet need, relieving patients of the significant physical and psychological impacts of the disease by providing renewed confidence and independence in day-to-day tasks without fear of regular, spontaneous bleeding.